Copyright
©The Author(s) 2003.
世界华人消化杂志. 2003-02-15; 11(2): 191-194
在线出版 2003-02-15. doi: 10.11569/wcjd.v11.i2.191
在线出版 2003-02-15. doi: 10.11569/wcjd.v11.i2.191
表1 LAP-SLN, LAP-GSLN和LA 对HBsAg和HBeAg抑制率n(%)
| 药名 | 浓度mg/L | 1 d | 2 d | 4 d | 6 d | 8 d | 10 d |
| LAP-SLN | 0.01 | 12.2(17.4) | 20.1(25.8) | 29.8(30.3) | 45.9(43.2) | 55.1(52.1) | 64.2(60.3) |
| 0.10 | 20.6(21.2) | 28.4(30.2) | 31.9(32.5) | 54.2(52.4) | 59.8(50.3) | 66.3(59.3) | |
| 1.00 | 23.4(23.6) | 32.0(32.5) | 39.9(40.3) | 53.3(51.4) | 64.9(55.2) | 70.2(55.2) | |
| 10.00 | 28.9(27.4) | 19.9(21.1) | 30.9(33.0) | 60.1(51.9) | 62.8(67.7) | 65.5(59.0) | |
| LAP-GSLN | 0.01 | 15.2(17.0) | 19.9(21.2) | 30.9(33.0) | 52.5(53.9) | 62.8(67.7) | 65.5(59.0) |
| 0.10 | 21.9(22.3) | 30.3(33.4) | 37.2(38.2) | 60.2(59.1) | 71.4(77.5) | 70.2(70.9) | |
| 1.00 | 28.7(29.0) | 36.9(40.3) | 44.7(45.3) | 60.4(54.3) | 71.3(69.2) | 71.9(68.4) | |
| 10.00 | 30.1(32.3) | 35.3(41.2) | 60.5(61.2) | 67.2(69.0) | 72.4(51.9) | 74.2(67.7) | |
| LA | 0.01 | 10.2(15.4) | 15.8(11.5) | 26.2(27.3) | 30.2(31.1) | 45.2(44.3) | 60.9(61.2) |
| 0.10 | 17.2(19.3) | 20.9(21.0) | 33.3(35.4) | 33.5(36.6) | 49.8(55.5) | 61.8(59.2) | |
| 1.00 | 20.3(21.6) | 29.8(29.6) | 40.1(39.2) | 42.7(41.2) | 56.2(40.2) | 59.6(60.3) | |
| 10.00 | 25.1(26.9) | 27.9(30.2) | 40.9(40.3) | 45.1(41.0) | 53.4(49.8) | 60.3(64.0) |
表2 给药30 min后LA在血清和脏器中的含量占总药量的百分比.
| 药物 | 血清 | 肝脏 | 肾脏 | 肺脏 | 脾脏 |
| LA | 40.0 | 39.4 | 12.8 | 6.4 | 1.4 |
| LAP-SLN | 25.2 | 52.1 | 12.7 | 7.3 | 2.7 |
| LAP-GLSN | 11.4 | 77.4 | 5.2 | 3.6 | 2.4 |
引文著录: 王九平, 白雪帆, 张三奇, 李谨革, 张颖, 张岩, 薛克昌, 顾宜, 王平忠, 骆抗先. 肝靶向十六酸拉咪呋啶酯固体脂质纳米粒抗乙肝病毒的研究. 世界华人消化杂志 2003; 11(2): 191-194